The Company’s scientific foundation is centered on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. Numerous diseases exhibit protein misfolding, among them certain cancers, and several neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. Accordingly, as its primary objective, the Company will focus on the discovery and development of precision therapeutics and companion diagnostics directed against the several strains of beta-amyloid (Aβ) and Tau in Alzheimer’s disease.
Core Science & Technology. The company is based around the leading science of Dr. Neil Cashman, Professor of Medicine at the University of British Columbia, Neuroscientist at the Brain Research Center, and Academic Director of the Vancouver Coastal Hospital ALS Center. For over two decades, Neil Cashman has been among the leaders in the field of misfolded proteins (with over 300 publications and over 10,000 citations and 45 patent applications), and is one of several leading researchers of strain specific protein misfolding. Misfolded proteins showing prion-like strains include: beta-amyloid (Aβ oligomers) in AD, superoxide dismutase1 (SOD1) and TDP43 in ALS, alpha-synuclein in PD, and Tau in multiple neurodegenerative diseases such as Alzheimer’s, chronic traumatic encephalopathy and certain forms of Parkinson’s.
Intellectual Property. Based primarily on the research discoveries in Dr. Cashman’s lab, the Company has exclusive access to critical IP and proprietary know-how in the field. The Company’s patent estate consists of eight patent families issued or pending. ProMIS™ Neurosciences, Inc. utilizes its computational discovery platform, ProMIS™, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. ProMIS™ Neurosciences, Inc. owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
Below is a webcast discussing exciting new research regarding the mechanisms driving Alzheimer’s disease, pointing toward a future of early diagnosis and effective treatment. Following the slide show presentation, we hold a short Q&A session to answer any questions the attendees had.